Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03513562 · ClinicalTrials.gov registry record · Phase 2

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

A Phase 2 study of Chronic Lymphocytic Leukemia and Ibrutinib Resistance, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
Phase 2
Development phase
28
Enrollment target
1
Study location

NCT03513562: Active Phase 2 study of Chronic Lymphocytic Leukemia and Ibrutinib Resistance, sponsored by Ohio State University Comprehensive Cancer Center.

NCT03513562 is a Phase 2 study of Chronic Lymphocytic Leukemia and Ibrutinib Resistance that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 28 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03513562, a Phase 2 study of Chronic Lymphocytic Leukemia and Ibrutinib Resistance, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well venetoclax and ibrutinib work in treating participants with chronic lymphocytic leukemia and have developed genetic mutations after previously being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Chronic Lymphocytic Leukemia Ibrutinib Resistance

Interventions

  • DRUG Venetoclax
  • OTHER Laboratory Biomarker Analysis
  • DRUG Ibrutinib

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2019-03-26
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Ohio State University Comprehensive Cancer Center

341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03513562

The ClinicalTrials.gov registry entry for NCT03513562 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (85% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Venetoclax is the first listed.

NCT03513562 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03513562 about?

NCT03513562 is a clinical study titled "Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations". This phase II trial studies how well venetoclax and ibrutinib work in treating participants with chronic lymphocytic leukemia and have developed genetic mutations after previously being treated with ibrutinib. Venetoclax and ibrutinib may stop the growth of cancer cells by blocking some of the enzym...

What is the current status of trial NCT03513562?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-03-26. Estimated completion is 2026-12-31.

What conditions does trial NCT03513562 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Ibrutinib Resistance.

What interventions are being tested in trial NCT03513562?

The interventions under investigation include: Venetoclax (DRUG), Laboratory Biomarker Analysis (OTHER), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT03513562?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03513562 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Ibrutinib Resistance

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.